TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30029855

Group type: EXPERIMENTAL
Intervention: Ivacaftor treatment for 3 months
Number of subjects: 23
Study: 30029866

Group type: EXPERIMENTAL
Intervention: WTC Health Registry participants (n=180)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Dust cloud exposure
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Home dust exposure
Number of subjects: 402

Group type: COMPARATOR
Intervention: Comparison group (n=222)
Number of subjects: 402
Study: 30030011

Group type: EXPERIMENTAL
Intervention: Rapid decline in estimated glomerular filtration rate over 2 years
Number of subjects: 0
Study: 30030617

Group type: EXPERIMENTAL
Intervention: Salivary adiponectin in patients with SS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salivary ADA in patients with SS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Salivary ADA in patients with non-SS sicca
Number of subjects: 17
Study: 30031087

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30031399

Group type: EXPERIMENTAL
Intervention: Large follicles
Number of subjects: 184

Group type: COMPARATOR
Intervention: Small follicles
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Gene expression of HAS2 and GDF9
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Other gene expressions studied (TNFAIP6, PTGS2, PTX3)
Number of subjects: 184
Study: 30031556

Group type: EXPERIMENTAL
Intervention: Sedation with intramuscular injection (olanzapine, droperidol, haloperidol, benzodiazepine, ketamine)
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Clinical events observed in agitated patients
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Delirium symptoms
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Characteristics associated with clinical events
Number of subjects: 1146
Study: 30031700

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 324
Study: 30031719

Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor (Reveal XT, Reveal Linq) implanted at 4 (3 to 6) days post-TAVR, continuous ECG monitoring for 12 months
Number of subjects: 103
Study: 30031863

Group type: EXPERIMENTAL
Intervention: Inorganic nitrate supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 0
Study: 30032103

Group type: EXPERIMENTAL
Intervention: Work-focused cognitive-behavioural therapy and individual job support
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1193
Study: 30032306

Group type: COMPARATOR
Intervention: Ischemia (IS) group
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Human study (acute phase)
Number of subjects: 165
Study: 30032426

Group type: EXPERIMENTAL
Intervention: Non-albuminuric renal impairment
Number of subjects: 15773

Group type: COMPARATOR
Intervention: Albuminuric forms of diabetic kidney disease (DKD)
Number of subjects: 15773
Study: 30032814

Group type: EXPERIMENTAL
Intervention: Avitinib (150-300 mg) twice daily for cycles of 28 days
Number of subjects: 16
Study: 30032875

Group type: EXPERIMENTAL
Intervention: Protocol management of neuromuscular block with neostigmine reversal
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 78
Study: 30032887

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25%, 20 ml with epinephrine 5 μg/ml
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (healthy male volunteers)
Number of subjects: 23
Study: 30033559

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PrEP offered to high-risk MSM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 0
Study: 30033644

Group type: EXPERIMENTAL
Intervention: Online group (online counselling and online, supervised, HIV self-testing)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Mixed group (online pre-test counselling and offline HIV testing)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Offline group (offline HIV counselling and testing)
Number of subjects: 571
Study: 30033738

Group type: COMPARATOR
Intervention: Placebo group from a previous randomized trial
Number of subjects: 6
Study: 30026911

Group type: EXPERIMENTAL
Intervention: Multi-platform information and communication technology intervention for neonatal resuscitation training; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard training for neonatal resuscitation; details on dosage and duration not available.
Number of subjects: 0
Study: 30035000

Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 21

Group type: COMPARATOR
Intervention: TD group
Number of subjects: 21
Study: 30035584

Group type: EXPERIMENTAL
Intervention: Frequent self-weighing
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Frequent self-weighing combined with binge eating
Number of subjects: 762
Study: 30036361

Group type: EXPERIMENTAL
Intervention: Audio-based mindfulness meditation program
Number of subjects: 53
Study: 30036892

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle aspiration (FNA) of benign lymph nodes, with a minimum of three passes.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 27
Study: 30037302

Group type: EXPERIMENTAL
Intervention: E-liac Stent Graft System
Number of subjects: 45
Study: 30037339

Group type: EXPERIMENTAL
Intervention: Education and supervised exercise (information from a physiotherapist and individually adapted exercises)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Education and supervised exercise
Number of subjects: 264

Group type: COMPARATOR
Intervention: Standard care (reference group)
Number of subjects: 264
Study: 30037629

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation with documented time to pulmonary vein isolation (Group 1)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation without documented time to pulmonary vein isolation (Group 2)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 1042
Study: 30037651

Group type: EXPERIMENTAL
Intervention: HEMS (Helicopter Emergency Medical Services)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (patients presenting directly to the Comprehensive Stroke Center)
Number of subjects: 33
Study: 30037888

Group type: EXPERIMENTAL
Intervention: CVDPoRT algorithm
Number of subjects: 104219
Study: 30038037

Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial therapy (EAT) including vancomycin and broad-spectrum beta-lactam
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial therapy (EAT)
Number of subjects: 333
Study: 30038051

Group type: EXPERIMENTAL
Intervention: Dietary fat intake after colon cancer diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30038390

Group type: EXPERIMENTAL
Intervention: Combined-intensified-modulated-adjuvant treatment including RT and hormone therapy (HT) after RP.
Number of subjects: 123
Study: 30038658

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 32
Study: 30038669

Group type: EXPERIMENTAL
Intervention: Highest quartile of LBP (Q4)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Waist circumference criterion met
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: LBP
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: LBP and sCD14
Number of subjects: 482
Study: 30038793

Group type: EXPERIMENTAL
Intervention: Group PM+ intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30038794

Group type: EXPERIMENTAL
Intervention: Multi-modal frailty intervention (tailored exercise program, protein supplementation, vitamin D supplementation, medication review)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-modal frailty intervention
Number of subjects: 0
Study: 30039172

Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCE) for ASCVD risk prediction
Number of subjects: 19995

Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCE) with CMS event linkage
Number of subjects: 19995

Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCE) overall
Number of subjects: 19995
Study: 30039554

Group type: EXPERIMENTAL
Intervention: Gilteritinib (20 to 300 mg/d, once daily)
Number of subjects: 24
Study: 30039634

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1 to 3 mg/day adjunct to current ADT
Number of subjects: 132
Study: 30040065

Group type: EXPERIMENTAL
Intervention: mpMRI
Number of subjects: 576

Group type: COMPARATOR
Intervention: TRUS-guided biopsy
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of mpMRI-based pathway
Number of subjects: 576
Study: 30040168

Group type: EXPERIMENTAL
Intervention: Prexasertib (80 mg/m)
Number of subjects: 0
Study: 30041608

Group type: EXPERIMENTAL
Intervention: Conbercept
Number of subjects: 5000
Study: 30041614

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (4 cycles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOLFOX (4 cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery followed by adjuvant chemotherapy (reference treatment)
Number of subjects: 0
Study: 30041626

Group type: COMPARATOR
Intervention: Traditional exercise (active control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tailored exercise
Number of subjects: 100
Study: 30041685

Group type: EXPERIMENTAL
Intervention: CO-IMPACT intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Enhanced usual primary care
Number of subjects: 240
Study: 30041785

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 654
Study: 30041962

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (NCRT)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Metabolomics profiling
Number of subjects: 106
Study: 30041971

Group type: EXPERIMENTAL
Intervention: Dopamine release capacity measured by percent change in baseline binding potential relative to nondisplaceable compartment (ΔBP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy comparison participants
Number of subjects: 26
Study: 30042063

Group type: EXPERIMENTAL
Intervention: Standard DCF regimen
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Modified DCF regimen
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Overall (both regimens)
Number of subjects: 66
Study: 30042144

Group type: EXPERIMENTAL
Intervention: Condensed MCMDM-1 VWD
Number of subjects: 120

Group type: COMPARATOR
Intervention: ISTH BAT
Number of subjects: 120
Study: 30042673

Group type: EXPERIMENTAL
Intervention: Choral singing intervention
Number of subjects: 0
Study: 30042675

Group type: COMPARATOR
Intervention: RTI-336
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30043115

Group type: EXPERIMENTAL
Intervention: Florbetaben injection (222-318.2 MBq, mean 270.1 ± 33.3 MBq)
Number of subjects: 9
Study: 30043168

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 174
Study: 30043210

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks with methotrexate
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 132
Study: 30044478

Group type: EXPERIMENTAL
Intervention: Active surveillance for stage I seminoma (89 patients, 57.8%)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for stage I seminoma (65 patients, 42.2%)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for high-risk stage I non-seminoma (23 patients)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Active surveillance for low-risk stage I non-seminoma (30 patients, 100%)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Radiotherapy for stage II seminoma (12 patients, 46.2%)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Chemotherapy for stage II seminoma (14 patients, 53.8%)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Chemotherapy for stage III seminoma (all patients)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Chemotherapy for stage II and III non-seminoma (all patients)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Non-compliance with guidelines (11 patients)
Number of subjects: 299
Study: 30044692

Group type: EXPERIMENTAL
Intervention: Ibrutinib monotherapy
Number of subjects: 0
Study: 30044693

Group type: EXPERIMENTAL
Intervention: Intensified treatment for IKZF1 deletion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 30044695

Group type: EXPERIMENTAL
Intervention: Contralateral prophylactic mastectomy (CPM)
Number of subjects: 288

Group type: COMPARATOR
Intervention: No contralateral prophylactic mastectomy (non-CPM)
Number of subjects: 288
Study: 30045714

Group type: EXPERIMENTAL
Intervention: Family Mindfulness-Based Intervention (MYmind): 8-week group-based MBI for youth combined with parallel group-based Mindful Parenting for parents, as an add-on to care-as-usual (CAU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care-as-usual (CAU) only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Family Mindfulness-Based Intervention (MYmind)
Number of subjects: 100
Study: 30045729

Group type: EXPERIMENTAL
Intervention: Shared Latrines (SL)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Community Sanitation Blocks (CSB)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional Latrine (TL)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Improved shared sanitation facilities (SL and CSB)
Number of subjects: 96
Study: 30045812

Group type: EXPERIMENTAL
Intervention: Tapered off maintenance immunosuppression
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NIH activity index over two
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Predictive equation based on activity index and duration of systemic lupus erythematosus
Number of subjects: 44
Study: 30045838

Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine (10 μg/kg) administered intravenously on the last day of hypomethylating agent (HMA) infusion (azacitidine or decitabine) in 4-week cycles.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine combined with HMAs.
Number of subjects: 53
Study: 30045932

Group type: EXPERIMENTAL
Intervention: ALT-803, a novel recombinant IL15 complex
Number of subjects: 0
Study: 30045949

Group type: EXPERIMENTAL
Intervention: Versi
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Embotrap
Number of subjects: 4

Group type: COMPARATOR
Intervention: Solitaire
Number of subjects: 4

Group type: COMPARATOR
Intervention: Trevo
Number of subjects: 4
Study: 30046225

Group type: EXPERIMENTAL
Intervention: Everyday regimen of amifostine
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Every-other-day regimen of amifostine
Number of subjects: 187

Group type: COMPARATOR
Intervention: No amifostine (control group)
Number of subjects: 187
Study: 30046307

Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 administration
Number of subjects: 0
Study: 30046464

Group type: EXPERIMENTAL
Intervention: Hybrid multifocal IOLs (OptiVis)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Monofocal IOLs
Number of subjects: 160

Group type: COMPARATOR
Intervention: Refractive multifocal IOLs
Number of subjects: 160
Study: 30046708

Group type: EXPERIMENTAL
Intervention: Idarucizumab (up to 5 g as two consecutive intravenous infusions over 5-10 minutes each)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 5
Study: 30046714

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin gel (1120 IU/100 g), administered 2-3 times daily for 16 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30046762

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study: 30046988

Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF) for 4 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Current diet (control group)
Number of subjects: 90
Study: 30048002

Group type: EXPERIMENTAL
Intervention: 1,25(OH) vitamin D metabolite
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 25OHD vitamin D metabolite
Number of subjects: 160
Study: 30048496

Group type: EXPERIMENTAL
Intervention: Disclosure to a sexual partner within a month of diagnosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Knowledge or strong suspicion about the source of infection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Assisted partner notification, individual and couples counseling, and couples HIV testing
Number of subjects: 40
Study: 30048507

Group type: EXPERIMENTAL
Intervention: Motor Function Measure (MFM) assessment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pulmonary function testing
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Strength assessment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Electroneuromyography
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Muscle imaging
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Workspace volume assessment
Number of subjects: 81
Study: 30049272

Group type: EXPERIMENTAL
Intervention: Behavioral activation therapy (BA)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 242
Study: 30049699

Group type: EXPERIMENTAL
Intervention: ReTrain intervention
Number of subjects: 45
Study: 30049701

Group type: EXPERIMENTAL
Intervention: Adolescents (aged 14-17 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young adults (aged 20-29 years)
Number of subjects: 0
Study: 30049743

Group type: EXPERIMENTAL
Intervention: Voriconazole monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30050047

Group type: EXPERIMENTAL
Intervention: GABA levels in the dACC
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Mediation analysis of GABA levels
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Other metabolites (creatine)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Frontal white matter control region
Number of subjects: 229
Study: 30050529

Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Natalizumab (NAT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NAT and FTY
Number of subjects: 15

Group type: COMPARATOR
Intervention: NAT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FTY
Number of subjects: 15
Study: 30051292

Group type: EXPERIMENTAL
Intervention: Patient management and treatment improvements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: International registry data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis and prognosis biomarkers
Number of subjects: 0
Study: 30051298

Group type: EXPERIMENTAL
Intervention: Daily application of a water-based, peelable nail polish
Number of subjects: 102

Group type: COMPARATOR
Intervention: 5% amorolfine nail lacquer (weekly application)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 102
Study: 30051724

Group type: EXPERIMENTAL
Intervention: Clindamycin for cellulitis
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Baseline procalcitonin levels
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 136
Study: 30052057

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients
Number of subjects: 48
Study: 30052269

Group type: EXPERIMENTAL
Intervention: Alectinib (300 mg single dose) in moderate hepatic impairment (n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alectinib (300 mg single dose) in severe hepatic impairment (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy subjects (n = 12)
Number of subjects: 16
Study: 30052304

Group type: EXPERIMENTAL
Intervention: HeartMate 3 Left Ventricular Assist System
Number of subjects: 50
Study: 30053006

Group type: EXPERIMENTAL
Intervention: 750 mg apatinib once a day (q.d.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 mg apatinib once a day (q.d.)
Number of subjects: 20
Study: 30053231

Group type: EXPERIMENTAL
Intervention: Post-operative AKI patients
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients without AKI but with positive post-operative CCA biomarkers
Number of subjects: 86

Group type: COMPARATOR
Intervention: Patients with neither clinical AKI nor positive biomarkers
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients who developed new CKD
Number of subjects: 86
Study: 30053671

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 875

Group type: COMPARATOR
Intervention: Endocrine therapy alone (letrozole or fulvestrant)
Number of subjects: 875
Study: 30053825

Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 20
Study: 30053861

Group type: EXPERIMENTAL
Intervention: Urban greening interventions (tree and flower planting, artificial tree decorations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched comparison sites (no interventions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urban greening interventions
Number of subjects: 0
Study: 30053905

Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg BID for 6 weeks followed by HD IL-2 (600,000 IU/kg every 8 hours on days 1-5 and days 15-19)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vemurafenib for 7-18 weeks followed by HD IL-2 (600,000 IU/kg every 8 hours on days 1-5 and days 15-19)
Number of subjects: 53
Study: 30053915

Group type: EXPERIMENTAL
Intervention: Age and sex as determinants of humoral immunity
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Genetic variants in the HLA class II region
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Total IgA levels
Number of subjects: 1000
Study: 30053953

Group type: EXPERIMENTAL
Intervention: Daily physical activity (number of steps per day)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 1-min sit to stand test (STS)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 6 min walking test (6MWT)
Number of subjects: 202
Study: 30054122

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg every 4 weeks for 3 months as an add-on to glucocorticoids (prednisone starting at 0.7 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 20